ATGAM General Investigation

Status Active, not recruiting

Clinical Trial Summary

The objective of this study is to confirm the safety of ATGAM in patients with moderate to severe aplastic anemia under the actual use in Japan. The registration criteria is patients with moderate to severe aplastic anemia who receive ATGAM. The observation period is 24 weeks (6 months) from the start of administration (Day 1). However, in cases where treatment has been completed or discontinued less than 24 weeks after the start of administration, observation is continued until completion (discontinuation) of treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06039020
Study type	Observational
Source	Pfizer
Contact
Status	Active, not recruiting
Phase
Start date	February 21, 2024
Completion date	February 13, 2026

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03025698` - A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia	Phase 2
Completed	`NCT00987480` - Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine	Phase 2
Completed	`NCT00767650` - Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia	N/A
Completed	`NCT02833805` - NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia	Phase 2
Not yet recruiting	`NCT02833493` - Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload	N/A
Recruiting	`NCT02028416` - Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia	N/A
Completed	`NCT00004474` - Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia	Phase 3
Recruiting	`NCT05031897` - Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant	Phase 2
Completed	`NCT04439006` - Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization	Phase 1
Not yet recruiting	`NCT05996393` - CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly	Phase 4
Completed	`NCT02462252` - Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome	Phase 2
Completed	`NCT00513175` - Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia	N/A
Completed	`NCT01272817` - Nonmyeloablative Allogeneic Transplant	N/A
Completed	`NCT00001398` - Stem Cell Factor Medication for Aplastic Anemia	Phase 1
Recruiting	`NCT01861093` - Safety Study of Cord Blood Units for Stem Cell Transplants	Phase 2
Not yet recruiting	`NCT05018936` - Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia	Phase 2/Phase 3
Completed	`NCT00065260` - Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia	Phase 2
Recruiting	`NCT02007811` - Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination	Phase 1/Phase 2
Recruiting	`NCT01758042` - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders	N/A
Terminated	`NCT01500161` - Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match	Phase 2